Skip to main content

Danaher Value Stock - Dividend - Research Selection

Danaher

ISIN: US2358511028 , WKN: 866197

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company\'s Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors. Its Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and flow cytometry products. The company offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians\' offices, reference laboratories, and other critical care settings. Its Dental segment provides consumables, equipment, and services to diagnose, treat, and prevent disease and ailments of the teeth, gums, and supporting bone. This segment offers implant systems, dental prosthetics, and associated treatment planning software; orthodontic bracket systems and lab products; endodontic systems and related consumables; restorative materials and instruments; infection prevention products; digital imaging systems and software; air and electric powered handpieces, and consumables; and treatment units. Its Environmental & Applied Solutions segment offers instrumentation, services, and disinfection systems to analyze, treat, and manage water in residential, commercial, industrial, and natural resource applications. This segment also provides equipment, software, services, and consumables for packaging, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


North America Mass Spectrometry Market Report 2025-2033, Profiles of Agilent Technologies, Bruker, Danaher, Hitachi, JEOL, LECO, PerkinElmer, and Thermo Fisher Scientific

2025-11-28
The North America Mass Spectrometry Market is poised to surge from US$ 2.6 Billion in 2024 to US$ 4.87 Billion by 2033, driven by a 7.21% CAGR. Key growth areas include pharmaceutical, environmental analysis, and food safety sectors, powered by advancements in mass spectrometry technology enhancing sensitivity and precision. Major drivers include increased demand in the pharmaceutical and biotechnology sectors, advancements in hybrid and high-resolution technologies, and growing applications in

North America Nucleic Acid Amplification Testing Market Analysis Report 2025-2033 - Technological Advances, Rising Diagnostic Demand, and Widespread Applications

2025-11-28
The North American Nucleic Acid Amplification Testing (NAAT) market will reach $7.64 billion by 2033, growing from $3.28 billion in 2024 with a CAGR of 9.87%. Driven by technological advances, rising diagnostic demand, and widespread applications, NAAT proves critical in identifying infectious diseases and genetic mutations. Notably, innovation, automation, and government support bolster the market's expansion. Despite regulatory hurdles and high costs, ongoing collaborations aim to enhance affo

Danaher (DHR) Q3 2025 Earnings Call Transcript

2025-11-28
With us today are Rainer Blair, our President and Chief Executive Officer; and Matt McGrew, our Executive Vice President and Chief Financial Officer. And with that, I'd like to turn the call over to Rainer.

Danaher (DHR): Evaluating the Stock’s Current Valuation After Recent Gains

2025-11-27
Danaher (DHR) stock has seen modest movement over the past month, gaining 3%. In contrast, the past three months marked a steadier 11% climb. Investors are weighing recent performance against the company’s longer-term trends. See our latest analysis for Danaher. Danaher's share price momentum has held up over the past quarter with a steady 11% gain, even as its 1-year total shareholder return remains slightly negative at -3.76%. This mix of recent strength and stagnant longer-term performance...

Revvity (RVTY) Up 9.5% Since Last Earnings Report: Can It Continue?

2025-11-26
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Danaher Stock: Is DHR Underperforming the Healthcare Sector?

2025-11-26
Despite Danaher’s underperformance relative to the healthcare sector, Wall Street analysts remain strongly optimistic about the stock’s prospects.

US STD Diagnostics Market Forecast and Company Analysis 2025-2033 Featuring Abbott, F. Hoffmann-La Roche, Hologic, BD and Co, Danaher, Siemens, bioMerieux, Thermo Fisher Scientific, Qiagen, Bio-Rad

2025-11-26
The United States STD Diagnostics Market is set to grow from US$ 5.06 billion in 2024 to US$ 8.49 billion by 2033, achieving a CAGR of 5.91% from 2025 to 2033. Key growth drivers include rising STD prevalence, technological advancements, increased awareness, and supportive government initiatives. Rapid point-of-care tests and molecular diagnostics are gaining traction, while high costs and regulatory hurdles persist as challenges. Major markets like California, Texas, New York, and Florida lead

DuPont Can Become a ‘Compounder.’ Why the Stock Could Gain 20%.

2025-11-25
Deutsche Bank analyst David Begleiter reiterated his Buy rating on the shares. His price target is $46

Estimating The Fair Value Of Danaher Corporation (NYSE:DHR)

2025-11-22
Key Insights The projected fair value for Danaher is US$218 based on 2 Stage Free Cash Flow to Equity With US$227 share...

Danaher Corp. stock underperforms Friday when compared to competitors despite daily gains

2025-11-21
Danaher Corp. stock underperforms Friday when compared to competitors despite daily gains